Preterm Premature Rupture of Membranes Clinical Trial
Official title:
Multimodales Monitoring Des Fetalen Inflammationsrisikos Bei frühem Vorzeitigen Blasensprung (PPROM)
The purpose of this study is to examine whether the value of vaginal fluid cytokine levels as well as computerized fetal ECG analysis are suitable clinical parameters to detect an imminent intra-amniotic inflammation with a high risk of fetal inflammatory response syndrome (FIRS) or a neonatal early onset sepsis (EOS) and whether these parameters can be determined on a daily basis in the clinical monitoring of pregnancies complicated by PPROM.
Preterm premature rupture of membranes (PPROM) is one of the leading causes for preterm birth
and adverse neonatal outcome. Between 24 0/7 and 34 0/7 weeks of gestation the prolongation
of pregnancy is the recommended course of action to reduce the risks of prematurity in most
countries. An intra-amniotic infection resulting in fetal inflammatory response syndrome
(FIRS) or early onset neonatal sepsis (EOS) is often associated with high morbidity and
mortality.
Standard monitoring includes the maternal response to inflammation (i.e. maternal serum
parameters) as well as fetal signs of acute FIRS (i.e. fetal tachycardia, high cytokine level
in amniotic fluid obtained by amniocentesis). Changes of fetal ECG-parameters are also a sign
of an acute FIRS.
Currently, there is no adequate parameter for the surveillance of a possible ongoing
intra-amniotic infection. Other studies have reported a correlation between vaginal fluid
interleukine 6 (IL6) collected noninvasively and the risk of FIRS and EOS. Information
obtained by computerized fetal ECG analysis might be suitable to detect early signs of fetal
infection before the manifestation of FIRS.
With the implementation of a vaginal fluid collector it is possible to detect the vaginal
fluid cytokine in clinical everyday routine. With the improvement of fetal ECG monitoring it
is possible to record the fetal ECG daily. This study examines the correlation between these
new parameters and the onset of fetal infection before the manifestation of a severe systemic
fetal inflammation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01431248 -
PPROM Erythromycin Versus Azithromycin
|
N/A | |
Active, not recruiting |
NCT04588220 -
Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM
|
||
Completed |
NCT02314728 -
Cervical Ripening in Premature Rupture of Membranes
|
N/A | |
Not yet recruiting |
NCT01152528 -
Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery
|
Phase 3 | |
Not yet recruiting |
NCT02635451 -
The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes
|
N/A | |
Completed |
NCT01266928 -
Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study
|
Phase 3 | |
Active, not recruiting |
NCT04532021 -
Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 Levels in PPROM
|
||
Recruiting |
NCT02548013 -
Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management
|
N/A | |
Recruiting |
NCT01584323 -
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
|
N/A | |
Recruiting |
NCT00466128 -
Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)
|
Phase 2 | |
Terminated |
NCT00463736 -
Magnesium Sulfate Versus Placebo for Tocolysis in PPROM
|
N/A |